Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: A retrospective study

Anticancer Research

Volumn 28, Issue 2 B, 2008, Pages 1433-1438

  Tsuji, Akihito ^a   Shima, Yasuo ^a   Morita, Sojiro ^a   Uchida, Mizuki ^a   Okamoto, Koichi ^a   Morita, Masanori ^a   Horimi, Tadashi ^a   Shirasaka, Tetsuhiko ^b  

^a Kochi Health Sciences Center   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Combination therapy; Gastric cancer; Low dose cisplatin; Outpatient setting; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONFIDENCE INTERVAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; OUTPATIENT; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR;

EID: 42549145902     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Heidelberger C, Shaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E and Scheiner J: Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179: 663-666, 1957.
2. Nakajima T: Gastric cancer treatment guidelines in Japan. Gastric Cancer 5: 1-5, 2002.
3. Chung Y, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, Maeda K, Sawada T, Kato Y, Shirasaka T and Sowa M: Continuous infusion of 5-fluorouracil and low-dose cisplatin infusion for treatment of advanced and recurrent gastric adenocarcinomas. Cancer 80: 1-7, 1997.
4. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K and Tanimoto M: Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 23: 1891-1897, 2003.
5. Kobayashi K, Tsuji A, Morita S, Horimi T, Shirasaka T and Kanematsu T: A phase II study of LFP therapy (5-FU (5-fluorouracil) continuous infusion (CVI) and low-dose consecutive (cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer 6: 121-131, 2006.
6. Tsuji A, Morita S, Horimi T, Takasaki M, Takahashi I and Shirasaka T: Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas. Gan To Kagaku Ryoho 27(Suppl 2): 528-534, 2000 (In Japanese.)
7. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
8. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H and Fukushima M: Inhibitation by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993.
9. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T and Shirasaka T: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5: 2000-2005, 1999.
10. Maehara Y: S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6(Suppl 1): 2-8, 2003.
11. Shirasaka T, Yamamitsu S, Tsuji A and Taguchi T: Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 18: 315-329, 2000.
12. Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T and Hirakawa K: Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). Clin Cancer Res 10: 1664-1669, 2004.
13. Rai K, Tsuji A, Morita S, Horimi T, Takamatsu M, Takahashi I and Shirasaka T: Continuous infusion of 5-FU and low-dose consecutive CDDP therapy in advanced hepatocellular carcinoma; a phase II study [abstract]. Proc Am Soc Clin Oncol 21: 655, 2002.
14. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, 2nd English edition. Tokyo, Kanehara, pp. 10-24, 1998.
15. National Cancer Institute Cancer Therapy Evaluation Program: Common Toxicity Criteria Manual, Common Toxicity Criteria, Version 2.0 June 1, 1999.
16. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y and Gotoh M: PhaseI/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003.
17. Hyodo I, Nishina T, Moriwaki T, Endo S, Terao T, Hirao K, Nasu J, Hirasaki S, Endo H, Masumoto T, Tajiri H and Kurita A: A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur J Cancer 39: 2328-2333, 2003.
18. Iwase H, Shimada M, Tsuzuki T, Horiuchi Y, Kumada S, Haruta J, Yamaguchi T, Sugihara M, Ina K, Kusugami K and Goto S: A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer. Anticancer Res 25: 1297-1302, 2005.
19. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Cancer Therapy 12: 3402-3407, 2006.
20. Takiuchi H, Narahara H, Tsujinaka T, Gotoh M, Kawabe S, Katsu K, Iishi H, Tatsuta M, Fujitani K, Furukawa H, Taguchi T; Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer. Jpn J Clin Oncol 35: 520-525, 2005.
21. Scanlon KJ, Newman EM, Lu Y and Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8925, 1986.
22. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H and Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer chemother Pharmacol 32: 167-172, 1993.
23. Araki H, Fukushima M, Kamiyama Y and Shirasaka T: Effect of consecutive lower-dose cisplatin in enhancement of fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett 160: 185-191, 2000.
24. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A and Ohtsu A; Gastrointestinal Oncology Study Group/ Japan Clinical Oncology Group: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912) [abstract]. J Clin Oncol 25: LBA4513, 2007.
25. Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, TS-1 Advanced Gastric Cancer (AGC) Clinical Trial Group: Randomized phase III study of S-1 alone versus S-1 plus cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial): S-1 plus cisplatin vs. S-1 in RCT in the treatment for stomach cancer [abstract]. J Clin Oncol 25: 4514, 2007.